Clinicians are encountering this dilemma more frequently as the indications for both OAC and DAPT expand. Through efforts to reduce thromboembolic events, the population of patients with AF and indications for OAC has broadened significantly. The development of the CHA 2 DS 2 -VASc (congestive heart failure, hypertension, age $75 years, diabetes mellitus, stroke/transient ischemic attack, vascular disease, age 65 to 74 years, sex category) risk score also expanded the number of patients with indications for anticoagulation (4), as the most recent major societal guidelines endorse a lower threshold to start OAC, using a CHA 2 DS 2 -VASc score of 1 as opposed to 2 (5,6).
Concurrently, emerging data support longer duration of DAPT (7) to reduce stent thrombosis and MACE.
With more patients on OAC and patients on DAPT for longer periods, the overlap of these 2 populations has inevitably grown as well. As physicians try to prevent adverse thrombotic events, more patients are being treated with more antithrombotic therapy. However, with the concurrent risk of bleeding, we must ask: is more antithrombotic therapy better? Or is it time to replace "more" with "better"?
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